ArQule To Report Second Quarter 2013 Financial Results On July 30, 2013

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the second quarter of 2013 on Tuesday, July 30, 2013 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.

Conference Call and Webcast
           
Date: Tuesday, July 30, 2013
Time: 9:00 a.m., Eastern Time
 

Conference Call Numbers
Domestic (toll free): (877) 868-1831
International: (914) 495-8595
Webcast:

www.arqule.com

A replay of the conference call will be available beginning two hours after the completion of the call through August 1, 2013 and can be accessed by dialing toll-free 855-859-2056 and outside the U.S. 404-537-3406. The confirmation code for replayed calls is 19175389.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621, designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.

Copyright Business Wire 2010